VRNA Earnings Prediction
The chart below shows how VRNA performed 10 days before and after its earnings report, based on data from the past quarters. Typically, VRNA sees a -5.34% change in stock price 10 days leading up to the earnings, and a -3.18% change 10 days following the report. On the earnings day itself, the stock moves by +5.24%. This data can give you a slight idea of what to expect for the next quarter's release.
VRNA Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
4.33M
--
--
Gross Margin
90.34%
--
--
Operating Margin
-723.10%
--
--
Net Margin
-763.90%
--
--
EPS
-0.05
-150.00%
-44.44%
No Data Available
VRNA Earnings Analysis
Verona Pharma plc Corporation (VRNA.O) Earnings Conference Call
Positive
Ohtuvayre Market Launch Success: Verona Pharma launched Ohtuvayre in the U.S., generating $5.6 million in net product sales for the third quarter, indicating strong market entry.
Clinical Trial Cost Surge: The company reported a significant increase in clinical trial costs, totaling $10.6 million for the quarter, compared to $3 million in the same period last year, reflecting robust R&D activity.
Strong Liquidity Position: Verona Pharma's cash and equivalents stood at $336 million as of September 30, 2024, ensuring strong liquidity for future operations.
Rapid Prescription Adoption: The company has successfully filled over 5,000 Ohtuvayre prescriptions within just 12 weeks of launch, demonstrating rapid adoption among healthcare providers.
Speaker Programs Engagement: Verona Pharma expects to have approximately 120 speaker programs completed by the end of 2024, enhancing engagement with healthcare professionals.
Negative
Sales Performance Challenge: Net product sales for the third quarter were $5.6 million, indicating a significant challenge in achieving higher sales figures.
Cost of Goods Sold: Cost of goods sold related to Ohtuvayre was $500,000 for the quarter, reflecting ongoing financial pressures.
Rising R&D Expenses: Research and development costs were $10.6 million for the quarter, a substantial increase from $3 million reported for the same period in 2023, indicating rising expenses in this area.
Increased Operational Costs: Selling, general and administrative expenses were $35.2 million for the quarter, compared to $13.4 million reported for the same period in 2023, highlighting increased operational costs.
Increased Net Loss: Net loss after tax was $43 million compared to a net loss after tax of $14.7 million for the same period in 2023, representing a worsening financial position.
VRNA FAQs
How does VRNA typically perform around its earnings report dates?
Is Verona Pharma plc (VRNA) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
VRNA Earning Call Sentiment
Verona Pharma plc (VRNA) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
VRNA.O
3.34%Positive
The earnings call highlights several concerns: increasing financial losses, competitive pressures, and management's reluctance to provide clear guidance. Despite positive FDA approval and market interest, the lack of a share repurchase program and significant rise in expenses overshadow initial sales success. The Q&A session revealed management's evasiveness on patient numbers and revenue expectations, adding uncertainty. Given the company's small market cap, these factors suggest a negative stock price movement in the short term.
